16:22
Public company Sonnet has postponed the merger vote to December 2.
BlockBeats news, on November 19, according to the latest documents, the US-listed company Sonnet Biotherapeutics has postponed the merger vote to December 2. Previously, on July 14, Sonnet BioTherapeutics agreed to an $888 million merger deal, which will rename the company to Hyperliquid Strategies and launch the HYPE fund strategy. The Nasdaq-listed Sonnet BioTherapeutics has agreed to merge with Rorschach I LLC to establish Hyperliquid Strategies and initiate the fund strategy. According to the press release issued on Monday, Rorschach I LLC is founded by...
HYPE-4.91%

